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Abstract
Background: Classic Whipple’s disease is caused by T. whipplei and likely involves genetic predispositions, such as
the HLA alleles DRB1*13 and DQB1*06, that are more frequently observed in patients. T. whipplei carriage occurs in
2-4% of the general population in France. Subclinical hypothyroidism, characterized by high levels of TSH and normal
free tetra-iodothyronine (fT4) dosage, has been rarely associated with specific HLA factors.
Methods: We retrospectively tested TSHus in 80 patients and 42 carriers. In cases of dysthyroidism, we tested the levels
of free-T4 and anti-thyroid antibodies, and the HLA genotypes were also determined for seven to eight patients.
Results: In this study, 72-74% of patients and carriers were male, and among the 80 patients, 14 (17%) individuals had
a high level of TSH, whereas none of the carriers did (p < 0 · 01). In the 14 patients with no clinical manifestations, the
T4 levels were normal, and no specific antibodies were present. Four patients treated with antibiotics, without thyroxine
supplementation, showed normal levels of TSHus after one or two years. One patient displayed a second episode
of subclinical hypothyroidism during a Whipple’s disease relapse five years later, but the subclinical hypothyroidism
regressed after antibiotic treatment. HLA typing revealed nine alleles that appeared more frequently in patients than
in the control cohort, but none of these differences reached significance due to the small size of the patient group.
Conclusion: Regardless of the substratum, classic Whipple’s disease could lead to subclinical hypothyroidism. We
recommend systematically testing the TSH levels in patients with Whipple’s disease.
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Background
Whipple’s disease, first described in 1907, is a chronic
infectious disease caused by Tropheryma whipplei [1,2].
The positive diagnosis of classic Whipple’s disease is based
on a positive histological assessment of a small bowel
biopsy [1-3]. In addition to classic Whipple’s disease, T.
whipplei also causes localized infections, such as endo-
carditis or encephalitis [1,4]. Although most individuals
can eradicate the bacteria after a primo-infection (gastro-
enteritis or bacteremia), [5,6] others remain asymptomatic
carriers [7], and an even smaller number of individuals
develop chronic disease [8]. Genetic predispositions are
strongly suspected in classic Whipple’s disease because
human populations are commonly exposed to T. whipplei
[9,10], yet individuals rarely develop classic Whipple’s
disease. Consistently, classic Whipple’s disease mainly
occurs in European middle-aged populations and has
not been described in Sub-Saharan African populations,
despite their high exposure to the bacterium [9]. Similarly,
patients frequently relapse, and different T. whipplei strains
can re-infect patients suffering from classic Whipple’s
disease, suggesting a lifetime susceptibility to this bacterium
[11-13]. Interestingly, a recent study highlighted that the
HLA alleles DRB1*13 and DQB1*06 occurred significantly
more frequently in patients with Whipple’s disease than in
healthy individuals exposed to the bacteria [10].
Among the hypothyroidism substratum, a broad range
of genetic defects has been reported, with different levels
of clinical consequences ranging from severe congenital
hypothyroidism [14-16] to unapparent manifestations in
some cases of thyroid-stimulating hormone (TSH)-resist-
ance [16]. Subclinical hypothyroidism is characterized by
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high TSH concentrations and normal serum thyroid
hormones or serum free thyroid hormones. In the
NHAES III study performed among US populations,
the prevalence of subclinical hypothyroidism was 4 · 3%,
associated with factors such as gender, age, body-mass
index, and dietary iodine intake [17]. In addition, the
prevalence of hyperthyroidism was higher in Europeans
than in African Americans, suggesting that genetic factors
also affect TSH secretion [17]. Among the causes of
subclinical hypothyroidism, chronic lymphocytic thyroid-
itis (Hashimoto’s) represents 60 to 80% of the cases [17],
but genetic factors, such as the HLA allele HLA-A*02,
have also been associated with autoimmune thyroid
disorders induced through interferon-alpha-therapy in
patients with chronic hepatitis C, and an association
of the HLA A2-B46-DR9 haplotype with autoimmune
thyroid dysfunction has also been described [10,18].
Some studies have reported the occurrence of hypo-
thyroidism during Whipple’s disease [2,19,20]. Interestingly,
a case of primary hypothyroidism with clinical mani-
festations was recently described, showing that the
requirement for thyroxine supplementation dramatically
and rapidly decreased after the initiation of antibiotic
treatment; indeed, supplementation could be stopped
after approximately 30 weeks, suggesting that T. whipplei
directly infects the thyroid [19]. In addition to the apparent
capacity of T. whipplei to infiltrate thyroid tissue [19],
we hypothesized that the risk of developing subclinical
hypothyroidism is also associated with host genetic factors.
Herein, we conducted a retrospective analysis of the
TSH concentrations in 122 individuals with either classic
Whipple’s disease (n = 80) or asymptomatic carriage of
T. whipplei (n = 42). We also investigated the HLA types
in patients suffering from hypothyroidism.
Methods
Patients
Since the first culture of T. whipplei in 2000, more than
27,000 T. whipplei PCR amplifications [21] have been
performed at our research center for the diagnosis of
more than 150 patients with classic Whipple’s disease
[1]. Among these patients, serum was obtained from 80
patients with a clear diagnosis of classic Whipple’s disease.
As a control, we used 42 patients with asymptomatic
carriage of T. whipplei for which serum were available [7].
Definition of classic Whipple’s disease and asymptomatic
carriage of T. whipplei.
A positive diagnosis of classic Whipple’s disease was ob-
tained through the histological assessment (PAS staining
and/or immunohistochemistry using antibodies specific
for T. whipplei) of a small bowel biopsy specimen [2,3].
Asymptomatic carriers were defined as patients without
clinical manifestations, showing positive T. whipplei PCR
amplification from a stool sample [22].
Table 1 Baseline characteristics of patients and carriers




Number of cases 80 42
Male 58 (72.5%) 31 (73.8%)
Mean age, years (range) 57.15 (28–84) 43.58 (18–80)
Frozen serum (stored < 5 years) 39 (48.1%) 19 (46.3%)
Frozen serum (stored < 5 years





















Figure 1 Time evolution of the TSH levels in four patients with CWD treated with antibiotics, without thyroxin supplementation.
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Laboratory findings
Serum selection and preservation
We tested retrospectively the TSHus levels in serum
samples aliquoted and stored at −80°C because of the
rarity of T. whipplei infections. To ensure that the stor-
age time did not affect our analysis, we selected frozen
samples from a wide range of times for the two groups
studied: from 2003 to 2011 for asymptomatic carriers
and from 2001 to 2012 for classic Whipple’s disease
patients. The number of samples stored before or within
the last five years was approximately equal in the two
groups (Table 1).
Serum tests
The electrochemiluminescence immunoassay (ECLIA) for
determination of TSH (thyroid-stimulating hormone), FT4
(free thyroxine hormone), anti-TPO (anti thyroid- specific
peroxidase auto antibodies) and anti-Tg (antithyroid-spe-
cific thyroglobulin auto antibodies) levels was performed
on a Cobas ® 6000 < e601 > analyzer (Roche Diagnostics,
D-68298 Mannheim, France).
A sandwich immunoassay was used to detect the TSH
levels, and a competition immunoassay was used to assess
the levels of FT4, anti-TPO and anti-Tg. In these assays,
the antigen-antibody complex binds to the solid phase via
biotin and streptavidin interactions. The reaction mixture
is subsequently aspirated into the measuring cell, where
the microparticles are magnetically captured onto the
surface of the electrode. The application of a voltage to
the electrode induces chemiluminescent emission, mea-
sured using a photomultiplier.
Figure 2 TSH levels in the CWD and asymptomatic carrier groups. The difference between the two groups is significant (P < 0.001).
Table 2 Factors associated with CWD based on multiple
logistic regression analyses
OR (95% CI) p-value
TSH 1.846 (1.186-2.875) 0.007
Age 1.058 (1.025-1.093) 0.001
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Normal serum level concentration
The serum level of TSH was normal when the concen-
tration ranged from 0 · 27 to 4 · 20 mUI/L. The serum
level of T4 was normal when the concentration ranged
from 12 to 22 pmol/L. The serum level of anti-thyroid
peroxidase antibodies and anti-thyroglobulin antibodies
was considered normal for concentrations <115 UI/mL
and <34 UI/mL, respectively.
HLA analysis
Patients and blood donors from southeast France were
genotyped for low resolution HLA-A, −B, −C, −DRB1
and –DQB1 loci using LABType SSO Typing Tests
(ONE LAMBDA, INC, USA) according to the manufac-
turer’s instructions, and the results were analyzed using
HLA Fusion v 1.2.1. software (ONE LAMBDA, INC, USA)
for allele identification. The control cohort (n = 130) was
obtained from southeast France (EFS Rhône Alpes, Histo-
compatibility Laboratory), and the data were obtained from
the Allele frequency net database [23].
Statistical analysis
Graph pad prism version 6.0 (La Jolla, USA) was used
for the statistical analyses shown in Figure 1. Statistical
significance was defined as P < 0 · 05. To exclude possible
confounding effects, such as age or gender, a logistic
regression model was used. The data analyses were
conducted using SPSS v.20 (SPSS Inc., Chicago, IL, USA).
Ethical statement
Informed consent was obtained from all the participating
patients in the study. The study was conducted as part of
normal care, without supplementary patient’s samples.
The study was approved by the Ethics Committee of the
Institut Fédératif de Recherche IFR48, Faculty of Medicine,
Marseille France (agreement number 13–028).
Results
Patient’s characteristics
Among the 80 patients with classic Whipple’s disease
and the 42 asymptomatic carriers, 58 (72 · 5%) and 31
Table 3 HLA-A, −B, −C, −DRB1 and -DQB1 types in
patients with hypothyroidism
HLA type Number of individuals Cohort vs. control
Locus Allele Hypothyroidism Control Odds Ratio P1
HLA-A
01 0 0% 36 28% N.A 0.19
02 5 71% 55 42% 3.41 > 0.2
03 2 29% 32 25% 1.23
24 2 29% 26 20% 1.60
26 1 14% 11 8% 1.80
29 1 14% 14 11% 1.38
32 1 14% 18 14% 1.04
68 2 29% 14 11% 3.31 0.19
Total 7 130
HLA-B
07 1 14% 19 15% 0.97
14 2 29% 12 9% 3.93 0.15
15 2 29% 20 15% 2.20
27 1 14% 8 6% 2.54
35 1 14% 20 15% 0.92
38 1 14% 5 4% 4.17 > 0.2
39 1 14% 6 5% 3.44 > 0.3
41 1 14% 4 3% 5.25 > 0.2
44 2 29% 34 26% 1.13
51 1 14% 15 12% 1.28
55 1 14% 8 6% 2.54
Total 7 130
HLA-C
03 3 43% 26 20% 3.00 0.16
04 1 14% 22 17% 0.82
05 2 29% 21 16% 2.08
06 1 14% 26 20% 0.67
07 3 43% 66 51% 0.73
08 2 29% 13 10% 3,60 0,17
12 1 14% 18 14% 1,04
15 1 14% 7 5% 2,93
Total 7 130
HLA-DRB1
01 2 25% 27 21% 2,29
03 1 13% 24 19% 0,63
04 2 25% 36 28% 0,87
07 1 13% 19 15% 0,83
08 1 13% 9 7% 1,92
11 3 38% 36 28% 1,57
13 3 38% 38 29% 1,45
14 1 13% 13 10% 1,29
15 1 13% 24 19% 0,63
Total 8 130
Table 3 HLA-A, −B, −C, −DRB1 and -DQB1 types in
patients with hypothyroidism (Continued)
HLA-DQB1
02 2 25% 37 29% 0,84
03 4 50% 93 72% 0,40 > 0.2
04 1 13% 5 4% 3,57 > 0.3
05 4 50% 48 37% 1,71
06 3 38% 56 43% 0,79
Total 8 130
Odds ratios ≥3 are highlighted in light gray, and odds ratios <0.5 are
highlighted in dark gray.
1: Two-tailed Fisher Exact Test.
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(73 · 8%) individuals, respectively, were male, and the
mean ages of the patient and carrier groups were 57 · 15
and 43 · 58 years, respectively.
Laboratory results
Among the 80 patients with classic Whipple’s disease, 14
individuals (17.5%) showed high levels of TSH compared
with the normal range (range: 4 · 28 to 12 · 43 mUI/L,
mean: 6 · 58 mUI/L) but normal free T4 concentrations.
Among these, 10 were male (71%) and the mean age was
58.28 years. None of these 14 individuals had another
cause of increased TSH or other comorbidity than
Whipple’s disease. Conversely, none of the 42 asymptom-
atic carriers showed an increase in the TSH concentration,
resulting in a significant difference between the two
groups (Figure 2). Using a multiple logistic regression
analysis, we showed that TSH is significantly higher in
classic Whipple’s disease, independent of the age of the
patients (P < 0 · 01) (Table 2).
Of the 14 patients with both classic Whipple’s disease
and discrepancies in the TSH serum levels, 13 patients
lacked positive anti-thyroglobulin and anti-thyroperoxidase
antibodies (the 14th patient could not be tested because of
an insufficient amount of serum) excluding a thyroiditis.
Evolution under antibiotic treatment
We retrospectively tested four patients for the evolution
of the TSH level after the initiation of antibiotic treatment
for classic Whipple’s disease. Three of these four patients
were treated with both doxycycline (200 mg/day) and
hydroxychloroquine (600 mg/day), and the fourth pa-
tient was treated with trimethoprim-sulfamethoxazole
(320 mg/1600 mg/day); none of these patients was treated
with thyroxine supplementation. We observed a dramatic
decrease in the TSH levels, particularly in the patient
showing the highest TSH levels at the time of diagnosis
(Figure 1).
Interestingly, one of the patients experienced a relapse
of Whipple’s disease at five years after cessation of the
antibiotic treatment (Figure 1, Patient 1), and at the
time of relapse, this patient also developed subclinical
hypothyroidism (TSH = 7 · 15 UI/L, normal T3 and T4
serum levels). Three months after resuming the anti-
biotic treatment (doxycycline and hydroxychloroquine),
the TSH levels were normal, although the patient had
not been treated with thyroxin supplementation.
HLA analysis
Among the 14 patients with classic Whipple’s disease and
subclinical hypothyroidism, seven individuals were typed
for HLA class I, and eight patients were typed for HLA
class II (Table 3). A comparison of the HLA frequencies
in these patients with those of a control cohort from
southeast France [23] revealed that nine alleles were
overrepresented in patients (odds ratio >3), including
HLA-A*02, which was observed in 5 of the 7 patients
(71%), but only in 55 of the 130 (42%) donors in the
control group. Despite these large odds ratios, none of
these comparisons reached significance due to the small
size of the patient group.
Discussion
Here, we described a significant association between
patients suffering from classic Whipple’s disease and
subclinical hypothyroidism. These results are particularly
reliable because we used stringent diagnosis criteria to
define classic Whipple’s disease, i.e., small bowel histo-
logical assessment (Figure 3) [3]. These findings were
based on techniques routinely used in biochemical ana-
lyses according to the manufacturer's instructions. The
influence of the serum preservation in our results was
also minimized because we used frozen aliquots of
serum stored at −80°C, representing the best preservation
conditions, and the number of serum samples tested
previously or within the last five years was comparable
Figure 3 Histological assessment of a duodenal biopsy with positive periodic acid-Schiff staining (A) and positive immunohistochemical
staining with polyclonal rabbit anti-T. whipplei antibody and Mayer’s haemalum counterstain (B).
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between the patient and carrier groups. Moreover, the
proportion of recently sampled or previously stored
serum was comparable among the 14 discrepant serum
samples (Table 1). The two groups were also comparable
in terms of gender proportion with a majority of male
as previously known in Whipple’s disease [1], but older
individuals were present in the patient group compared
with the carrier group (Tables 1 and 2). Nevertheless,
these results are significant because the multiple logistic
regression analysis revealed that the association between
higher TSH and classic Whipple’s disease is independent
of the age of patients (Table 2). Finally, we observed a
proportion of patients with subliclinical hypothyroidism
(17%) significantly highest compared with general popula-
tion (from 3% to 4%) [17].
The characteristics of the symptoms associated with
subclinical hypothyroidism, which are neither sensitive
nor specific [17] could explain the underdiagnosis of
classic Whipple’s disease. Despite controversies regarding
whether to treat with thyroxin supplementation in these
cases, [17,24,25] the early detection of TSH disorders
could reveal conditions associated with the risk of devel-
oping thyroid disease [17] and consequently an increasing
risk of both cardiovascular diseases and heart failure. T.
whipplei can spread to various tissues and fluids [1,2],
leading to thyroid tissue infiltration, and this model is
supported by the regression of biological discrepancies
under adapted antibiotic treatment [19] and the elimin-
ation of other classic causes of subclinical hypothyroidism
[17]. However, in previously described cases, thyroid
cytology aspirations were PAS-negative, and the T.
whipplei PCR amplification failed in two different
samples [19]. A strong relationship between T. whipplei
and subclinical hypothyroidism was demonstrated in a
patient showing successive subclinical hypothyroidism
during two different disease relapses, which was regressive
in both cases after antibiotic initiation.
Hypothyroidism and classic Whipple’s disease have
been recently associated with specific HLA types. Here,
we observed an overrepresentation of nine HLA alleles
(HLA-A*02, A*68, B*14, B*38, B*39, B*41, C*03, C*08,
DQB1*04) (Table 3) in patients with classic Whipple’s
disease and subclinical hypothyroidism, but these dif-
ferences did not reach significance, likely reflecting the
small number of patients investigated; thus, a larger
cohort could confirm the results of Martinetti et al.
[10] regarding HLA and Whipple’s disease and will be
necessary to confirm these initial observations regarding
an association with subclinical hypothyroidism .
Conclusions
Despite the cause of subclinical hypothyroidism, in the
present study, we demonstrated an increased risk in
patients with classic Whipple’s disease that is not present
in T. whipplei asymptomatic carriers. Consequently, we
recommend both prospective and systematic testing of the
TSH and T4 serum concentrations in patients with classic
Whipple’s disease. Because of the subclinical nature and
the reversibility under antibiotic treatment, we not recom-
mend a thyroxin supplementation and to control after
1 month of antibiotics.
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